HER2-Positive Breast Cancer

Study Finds Patients with HER2+ Breast Cancer Live Longer if Anti-Cancer Drugs Induce pCR
October 25, 2020

A study which evaluated lapatinib (Tykerb) and trastuzumab (Herceptin) given prior to surgery in patients with early HER2-positive breast cancer revealed that women who had a pathological complete response survived longer without the cancer returning than those who did not.

Gregory Vidal, MD, PhD, on Treating Patients with HER2+ Breast Cancer During COVID-19
October 16, 2020

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

Addition of Tucatinib to Trastuzumab, Capecitabine Improves Survival in HER2+ mBC
September 21, 2020

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.